Clinical trial · Observational
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
NCT05817604CI-TRIAL-00077025SABINAactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study evaluating the activity and efficacy of Stereotactic Body Radiotherapy for the treatment of medically inoperable localized renal cancer
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Inoperable Disease | — | UNRESOLVED | — |
| Kidney Neoplasm | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Renal Cancer | — | UNRESOLVED | — |
| SABR | — | UNRESOLVED | — |
| SBRT | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SBRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Localized Renal Cancer-One arm
- description
- Patients diagnosed with medically inoperable localized renal cancer \[Size \<7cm (cT1b)\] based on TC, MRI or PET Image Study.
- interventionNames
- Radiation: SBRT
Primary outcomes (1)
- measure
- Local relapse-free survival
- timeFrame
- Participants should be followed continuously during 5 years
- description
- Local Control assessed by RECISTv1.1 criteria with TC, MRI or PET-scan
Secondary outcomes (5)
- measure
- Metastases-Free Survival
- timeFrame
- Participants should be followed continuously during 5 years
- description
- Metastases-Free Survival assessed by RECISTv1.1 criteria with TC, MRI or PET-scan
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of Renal tumor and/or highly suspected malignant neoplasm by CT, MRI or PET. * Tumor Diameter \>1cm - \<7cm * Tumor visible on CT planning * Medically inoperable disease (or rejection of surgery) * Karnofsky Index \>70% * \>18 y.o. * Informed Consent signature Exclusion criteria: * Non-oncological renal disease or autoinmunological disorder that does not recommend the treatment with radiotherapy. * Previous local/regional RT * Life expectancy \<6 months * Concomitance with other antineoplastic drugs
References
Publications (0)
Data not yet available
No reference posted for this study.